Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 20/20 | 0.71 |
| ▸ | PIK3CG | P48736 | 16/20 | 0.71 |
| ▸ | PIK3R1 | P27986 | 7/20 | 0.71 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 6/20 | 0.51 |
| ▸ | PRKDC | P78527 | 2/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11397 | 1.00 | PIK3CD (0.71) | PIK3CDPIK3CGPIK3R1PIK3CAPIK3CB | |
| SCHEMBL11213 | 0.94 | PIK3CD (0.81) | PIK3CDPIK3CGPIK3R1PIK3CAPIK3CB | |
| SCHEMBL31655812 | 0.94 | PIK3CD (0.81) | PIK3CDPIK3CGPIK3R1PIK3CAPIK3CB | |
| SCHEMBL31655833 | 0.93 | PIK3CD (0.71) | PIK3CDPIK3CGPIK3R1PIK3CAPIK3CB | |
| SCHEMBL11474 | 0.93 | PIK3CD (0.71) | PIK3CDPIK3CGPIK3R1PIK3CAPIK3CB | |
| SCHEMBL12116 | 0.93 | PIK3CD (0.73) | PIK3CDPIK3CGPIK3R1PIK3CAPIK3CB | |
| SCHEMBL31655772 | 0.93 | PIK3CD (0.73) | PIK3CDPIK3CGPIK3R1PIK3CAPIK3CB | |
| SCHEMBL31655781 | 0.92 | PIK3CD (0.72) | PIK3CDPIK3CGPIK3R1PIK3CAPIK3CB | |
| SCHEMBL11940 | 0.92 | PIK3CD (0.72) | PIK3CDPIK3CGPIK3R1PIK3CAPIK3CB | |
| SCHEMBL31655806 | 0.90 | PIK3CD (0.69) | PIK3CDPIK3CGPIK3R1PIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12350302-B2 | Dosing regime and formulations for type B adenoviruses | Akamis Bio Limited (GB) | 2025-07-08 | — | — | US | disclosed |